en · de · es · fr · pt
sr9009-notes.peptides6088.com › Data › Background And Receptor Mechanism — Complete Guide

Background And Receptor Mechanism — Complete Guide

By Editorial Desk · published 2026-01-03 · last reviewed 2026-01-25 · Data

REV-ERB is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

SR9009 Handling and Quality Control

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Detection, Regulation, and Misconceptions

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Related pages on this site

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Further detail

=== Membrane lipid biosynthesis === There are two major classes of membrane lipids: glycerophospholipids and sphingolipids. Although many different membrane lipids are synthesized in our body, pathways share the same pattern. The first step is synthesizing the backbone (sphingosine or glycerol), the second step is the addition of fatty acids to the backbone to make phosphatidic acid. Phosphatidic acid is further modified with the attachment of different hydrophilic head groups to the backbone. Membrane lipid biosynthesis occurs in the endoplasmic reticulum membrane.

=== Netherlands === The Parliament of the Netherlands is known as the Staten-Generaal, the States General. It is bicameral, divided into two kamers (English: chambers). The Senate is known in Dutch as the Eerste Kamer (First Chamber) and its members as senatoren, senators. The House of Representatives, known in Dutch as the Tweede Kamer (Second Chamber), is the most important one. The important debates take place here. Also, the Second Chamber can amend proposed laws and can propose laws itself. The Senate does not have these capabilities. Its function is a more technical reviewing of laws. It can only pass a law or reject it. Both chambers are in The Hague, which is the seat of parliament but not the official capital of the Netherlands, which is Amsterdam. The 150 members of the House of Representatives are elected by general elections every four years (or earlier if the government falls). The 75 members of the Senate are elected indirectly. The members of the twelve provincial parliaments and the councils of the three Caribbean special municipalities elect the senators. The value of a vote of a member of a provincial parliament is weighted by the population of the province. Provincial parliaments, the States Provincial, are elected by general elections every four years; a new Senate is elected three months after the provincial elections.

== Pathophysiology == SJS is a type IV hypersensitivity reaction in which a drug or its metabolite stimulates cytotoxic T cells (i.e. CD8+ T cells) and T helper cells (i.e. CD4+ T cells) to initiate autoimmune reactions that attack self tissues. In particular, it is a type IV, subtype IVc, delayed hypersensitivity reaction dependent in part on the tissue-injuring actions of natural killer cells. This contrasts with the other types of SCARs disorders, i.e., the DRESS syndrome which is a Type IV, Subtype IVb, hypersensitivity drug reaction dependent in part on the tissue-injuring actions of eosinophils and acute generalized exanthematous pustulosis which is a Type IV, subtype IVd, hypersensitivity reaction dependent in part on the tissue-injuring actions of neutrophils. Like other SCARs-inducing drugs, SJS-inducing drugs or their metabolites stimulate CD8+ T cells or CD4+ T cells to initiate autoimmune responses. Studies indicate that the mechanism by which a drug or its metabolites accomplishes this involves subverting the antigen presentation pathways of the innate immune system. The drug or metabolite covalently binds with a host protein to form a non-self, drug-related epitope. An antigen presenting cell (APC) takes up these alter proteins; digests them into small peptides; places the peptides in a groove on the human leukocyte antigen (i.e. HLA) component of their major histocompatibility complex (i.e. MHC); and presents the MHC-associated peptides to T-cell receptors on CD8+ T cells or CD4+ T cells.

Sources: en.wikipedia.org

Background from the literature

== Disorders and conditions == Numerous reports have been published indicating that the glutamate/GABA–glutamine cycle is compromised in a variety of neurological disorders and conditions. Biopsies of sclerotic hippocampus tissue from human subjects with epilepsy have shown decreased glutamate–glutamine cycling. Another pathology in which the glutamate/GABA–glutamine cycle might be compromised is Alzheimer's disease; NMR spectroscopy showed decreased glutamate neurotransmission activity and TCA cycling rate in patients with Alzheimer's disease. Hyperammonemia in the brain, typically occurring as a secondary complication of primary liver disease and known as hepatic encephalopathy, is a condition that affects glutamate/GABA–glutamine cycling in the brain. Current research into autism also indicates potential roles for glutamate, glutamine, and/or GABA in autistic spectrum disorders.

Over the coming decade, Libya developed stronger political and economic links with Dom Mintoff's Maltese administration, and under Libya's urging Malta did not renew the UK's airbases in 1980. Orchestrating a military build-up, the RCC began purchasing weapons from France and the Soviet Union. The commercial relationship with the latter led to an increasingly strained relationship with the US, which was then engaged in the Cold War with the Soviets.

== Epidemiology == An estimate of in the order of 1000 dive injuries per year occur in the United States and Canada. Many of these involve barotrauma, with nearly 50% of reported injuries involving middle ear barotrauma. Diving injuries tend to correlate with trait anxiety and a tendency to panic, lack of experience, advancing age and reduction in fitness, alcohol usage, obesity, asthma, chronic sinusitis and otitis.

Sources: en.wikipedia.org

Further detail

== Partitioning and transmutation strategy == Many efforts are being devoted to develop an advanced reprocessing approach with the aim to further reduce the radiotoxicity inventory of the spent nuclear fuel by removing all minor actinides (Neptunium, Americium and Curium) and the long-lived fission products (LLFP) from the high active raffinate downstream of the PUREX process. Before the conditioning process, the long-lived radionuclides undergo a transmutation into short-lived or stable nuclides by nuclear reactions. This coupled approach is known as Partitioning and Transmutation strategy (P&T), which inclusion in an advanced closed fuel cycle could lead to strongly reduce long-term radiotoxicity, volume and decay heat of the final waste thus simplifying a performance assessment of a future nuclear waste repository and enhancing proliferation resistance criteria. Two potential process options for the partitioning of spent nuclear fuel are being developed: hydrometallurgical and pyrometallurgical processes. The hydrometallurgical partitioning, also known as solvent extraction process, was born and developed in Europe thereby becoming the reference technology for future SNF reprocessing at industrial level, whereas the pyrometallurgical option started in the United States and Russia as an alternative to the aqueous processes.

==== Initial outbreak ==== In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) was first identified in Wuhan, Hubei, China; it spread worldwide and was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020. The first confirmed case in Canada was in Ontario—reported on January 27, 2020. On March 17, Ford declared a state of emergency in Ontario, closing bars and restaurants (with the exception of take-out and delivery services), as well as libraries, theatres, cinemas, schools and daycares and all public gatherings of more than 50 people (later reduced to 5 people on March 28). Furthermore, the government announced on March 17 that Ontario had "some evidence of community transmission" of COVID-19. On March 23, Ford announced that all "non-essential" businesses would be ordered closed starting 11:59 p.m. On March 24. Ford also stated that schools would remain closed past the original April 6 opening date (on May 19 it was announced that schools would remain closed until the following school year in September). A list of 74 "essential" businesses was published later in the day on March 23. On March 25, Ford and Finance Minister Rod Phillips introduced a $17-billion response package that includes an influx of cash for the health sector, direct payments to parents and tax breaks for businesses.

== East Africa == Its East Africa, laboratories include Pathologists Lancet Kenya Limited, established in 2009. Others include Lancet Laboratories Uganda Limited and Lancet Laboratories Tanzania Limited.

Extended-release (or slow-release) formulations of morphine are those whose effect lasts substantially longer than bare morphine, availing for, e.g., one administration per day. Conversion between extended-release and immediate-release (or "regular") morphine is easier than conversion to or from an equianalgesic dose of another opioid with different half-life, with less risk of altered pharmacodynamics.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network